RIPK1 and Sepsis: Importantly, in preclinical sepsis models, small-molecule RIPK1 inhibitors, such as necrostatins, have shown promising protective effects: Necrostatin-1 blocks RIPK1 kinase activity, limiting necrosome formation and downstream inflammation in experimental models of systemic inflammation and lung or kidney injury [51,52,53,54].